Lademirsen

N/A

Report date: 2025/07/03 15:42:26
NME

Base Information

Drug NameLademirsen
Drug Alias NameLademirsen sodiumRG-012SAR-339375RG-456070
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionmicroRNA 21 inhibitors
TargetsmicroRNA 21
Therapy Area/IndicationsNephritis, Hereditary
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaGermany +[7] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesSanofiRegulus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi AventisSanofi Us Services IncLyophilization Services Of New England Inc +[6] 
Active IndicationsN/A
Inactive IndicationsNephritis, Hereditary

Other Information

ATC CodeN/A
Related LinksN/A